GlassScriptPhysician profile
Meredith Seales
NPI 1558902627
$1,237.50
in general payments reported to CMS, 2019-2025
21 companies · $539 in 2025
The $539 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $14.27 · 2023: $330 · 2024: $354 · 2025: $539.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,185 · Education: $38.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,184.69 |
| Education | $38.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $178.97 | 2023-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $150.12 | 2023-2025 | Breztri, Farxiga, Airsupra |
| Exact Sciences Corporation | $147.86 | 2023-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $115.98 | 2023-2024 | Mounjaro, Zepbound, Jardiance |
| Lundbeck LLC | $94.94 | 2024-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $71.60 | 2025 | Spravato |
| Pfizer INC. | $66.88 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $52.74 | 2023-2025 | Gardasil 9, Vaxneuvance, Capvaxive |
| Novo Nordisk INC | $47.79 | 2024-2025 | Wegovy |
| Axsome Therapeutics, INC. | $44.25 | 2025 | Auvelity |
| Amgen INC. | $38.19 | 2023-2025 | Evenity, Prolia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $35.40 | 2024-2025 | Xifaxan |
| Azurity Pharmaceuticals, INC. | $28.45 | 2024-2025 | |
| Abbvie INC. | $28.25 | 2024-2025 | |
| Dexcom, INC. | $23.57 | 2024 | Dexcom G6 Transmitter |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $23.54 | 2024 | |
| Seqirus USA INC | $20.99 | 2024 | Fluad, Flucelvax |
| Abbott Laboratories | $19.44 | 2024 | Alere Cholestech Ldx |
| Supernus Pharmaceuticals, INC. | $17.64 | 2025 | Qelbree |
| Astellas Pharma US INC | $16.63 | 2025 | Veozah |
| Avanir Pharmaceuticals, INC. | $14.27 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meredith Seales listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.